One ticker, one page: health score, red flags, fundamentals, who’s buying, cash & dilution, and the latest catalyst — every module built from SEC filings, ready to print or share.
start from a preset — you get the bundle, then edit it
or pick exactly what you want — 5 selected
These add one extra lookup each — still fine to combine.
Heavy modules — each one runs on its own. Checking one clears the rest, because it reads several filings live and would otherwise time the page out.
Your selection lives in the link, so a built report is shareable and bookmarkable. Educational information from public filings — not investment advice.
Assembling APUS’s research report…
Pulling SEC filings
Parsing XBRL fundamentals
Scoring quality, value & momentum
Checking who’s buying
Rendering
APUS Research Report — Health D | StockTools.ai
APUS Apimeds Pharmaceuticals US, Inc.
Research report · from SEC EDGAR · close 2026-08-12
Apimeds Pharmaceuticals US, Inc. (APUS) is a $70.3M company. It is not yet profitable. Our health score is D (45/100). 1 red flag on file. It may need to raise cash (dilution risk).
No per-share dividend series in APUS’s filings — either it pays none, or it doesn’t report the tag we read. We show nothing rather than estimate.
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-08-12 by stocktools.ai.